JITC

Phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer: primary analysis in the original cohort of KGOG3046/TRU-D
Junsik Park, Jung Bok Lee, Myong Cheol Lim, Byoung-Gie Kim, Jae-Weon Kim, Sunghoon Kim, Chel Hun Choi, Hee Seung Kim, Sang Yoon Park, Jung-Yun Lee

Journal for ImmunoTherapy of Cancer Oct 2023, 11 (10) e007444; DOI: 10.1136/jitc-2023-007444
Classification of the tumor immune microenvironment and associations with outcomes in patients with metastatic melanoma treated with immunotherapies
Nurudeen A Adegoke, Tuba N Gide, Yizhe Mao, Camelia Quek, Ellis Patrick, Matteo S Carlino, Serigne N Lo, Alexander Maxwell Menzies, Ines Pires da Silva, Ismael A Vergara, Georgina Long, Richard A Scolyer, James S Wilmott

Journal for ImmunoTherapy of Cancer Oct 2023, 11 (10) e007144; DOI: 10.1136/jitc-2023-007144
Pretreatment radiomic biomarker for immunotherapy responder prediction in stage IB–IV NSCLC (LCDigital-IO Study): a multicenter retrospective study
Shaowei Wu, Weijie Zhan, Lan Liu, Daipeng Xie, Lintong Yao, Henian Yao, Guoqing Liao, Luyu Huang, Yubo Zhou, Peimeng You, Zekai Huang, Qiaxuan Li, Bin Xu, Siyun Wang, Guangyi Wang, Dong-Kun Zhang, Guibin Qiao, Lawrence Wing-Chi Chan, Michael Lanuti, Haiyu Zhou

Journal for ImmunoTherapy of Cancer Oct 2023, 11 (10) e007369; DOI: 10.1136/jitc-2023-007369
Vaccination with post-translational modified, homocitrullinated peptides induces CD8 T-cell responses that mediate antitumor immunity
Sabaria Shah, Katherine W Cook, Peter Symonds, Juliane Weißer, Anne Skinner, Abdullah Al Omari, Samantha J Paston, Ian Pike, Lindy G Durrant, Victoria A Brentville

Journal for ImmunoTherapy of Cancer Oct 2023, 11 (10) e006966; DOI: 10.1136/jitc-2023-006966
Analysing the tumor transcriptome of prostate cancer to predict efficacy of Lu-PSMA therapy
Analena Handke, Claudia Kesch, Wolfgang Peter Fendler, Tugce Telli, Yang Liu, Alexander Hakansson, Elai Davicioni, Jason Hughes, Hong Song, Katharina Lueckerath, Ken Herrmann, Boris Hadaschik, Robert Seifert

Journal for ImmunoTherapy of Cancer Oct 2023, 11 (10) e007354; DOI: 10.1136/jitc-2023-007354
Divergent tumor and immune cell reprogramming underlying immunotherapy response and immune-related adverse events in lung squamous cell carcinoma
Minjiang Chen, Pengfei Ma, Yongchang Zhang, Dong Wang, Zhuang Yu, Yujie Fu, Xiaojing Zhao, Mengzhao Wang, Guanglei Zhuang, Ying Jing

Journal for ImmunoTherapy of Cancer Oct 2023, 11 (10) e007305; DOI: 10.1136/jitc-2023-007305
Identification of tumor-intrinsic drivers of immune exclusion in acral melanoma
Ryan C Augustin, Sarah Newman, Aofei Li, Marion Joy, Maureen Lyons, Mary P Pham, Peter Lucas, Katelyn Smith, Cindy Sander, Brian Isett, Diwakar Davar, Yana G Najjar, Hassane M Zarour, John M Kirkwood, Jason John Luke, Riyue Bao

Journal for ImmunoTherapy of Cancer Oct 2023, 11 (10) e007567; DOI: 10.1136/jitc-2023-007567
AdvanTIG-105: a phase I dose escalation study of the anti-TIGIT monoclonal antibody ociperlimab in combination with tislelizumab in patients with advanced solid tumors
Sophia Frentzas, Steven Kao, Rang Gao, Hao Zheng, Ahsan Rizwan, Nageshwar Budha, Luz de la Hoz Pedroza, Wei Tan, Tarek Meniawy

Journal for ImmunoTherapy of Cancer Oct 2023, 11 (10) e005829; DOI: 10.1136/jitc-2022-005829
Increased interleukin-6/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic resistance to immune checkpoint inhibitor-based therapies in non-small cell lung cancer
Abdul Rafeh Naqash, Justin D McCallen, Emma Mi, Sanna Iivanainen, Mona A Marie, Daria Gramenitskaya, James Clark, Jussi Pekka Koivunen, Shravanti Macherla, Sweta Jonnalagadda, Shanker Polsani, Rahim Ali Jiwani, Maida Hafiz, Mahvish Muzaffar, Leonardo Brunetti, Chipman R G Stroud, Paul R Walker, Kun Wang, Youngmin Chung, Eytan Ruppin, Se-Hoon Lee, Li V Yang, David J Pinato, Joo Sang Lee, Alessio Cortellini

Journal for ImmunoTherapy of Cancer Oct 2023, 11 (10) e007310; DOI: 10.1136/jitc-2023-007310
Phase II trial of nivolumab and metformin in patients with treatment-refractory microsatellite stable metastatic colorectal cancer
Mehmet Akce, Batoul Farran, Jeffrey M Switchenko, Manali Rupji, Sandra Kang, Lana Khalil, Amanda Ruggieri-Joyce, Brian Olson, Walid L Shaib, Christina Wu, Olatunji B Alese, Maria Diab, Gregory B Lesinski, Bassel F El-Rayes

Journal for ImmunoTherapy of Cancer Oct 2023, 11 (10) e007235; DOI: 10.1136/jitc-2023-007235

Main menu

JITC

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

JITC

Pages